Logo
x

Search

Subscribe Now

All Posts by Date

PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)

PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for C...

  • June 20, 2022
Novartis Publishes Results from Two and Three-Copy Cohorts of Zolgensma in P-III (SPR1NT) Trial for Spinal Muscular Atrophy in the Nature Medicine

Novartis Publishes Results from Two and Three-Copy Cohorts of Zolgensma in P-III (SPR1NT) Trial for Spinal Muscular Atrophy in the...

  • June 20, 2022
BMS Reports EMA's Validation of Type II Variation Application for Breyanzi (lisocabtagene maraleucel) to Treat R/R Large B-cell Lymphoma

BMS Reports EMA's Validation of Type II Variation Application for Breyanzi (lisocabtagene maraleucel) to Treat R/R Large B-cell Ly...

  • June 20, 2022
Myovant and Pfizer Report Result of Relugolix Combination Therapy in P-III (SPIRIT 1 & 2) Studies for Endometriosis-Associated Pain

Myovant and Pfizer Report Result of Relugolix Combination Therapy in P-III (SPIRIT 1 & 2) Studies for Endometriosis-Associated Pai...

  • June 20, 2022
AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease

AbbVie’s Skyrizi (risankizumab-rzaa) Receives the US FDA’s Approval as the First Specific Interleukin-23 to Treat Moderately to Se...

  • June 20, 2022
Zura Bio to Go Public via JATT SPAC Merger for ~$215M

Zura Bio to Go Public via JATT SPAC Merger for ~$215M

  • June 20, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.